Health & Biotech
PharmAust Limited (ASX:PAA) is a clinical-stage biotechnology company developing therapeutics for human and animal health applications.
The company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases and treating cancer in dogs. MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in cell growth and proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular “cleaning process”, where toxic protein is broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including motor neurone disease (MND/ALS).
PAA’s lead MPL program is for the treatment of MND/ALS, a rare, incurable disease. The company is currently completing a Phase 1 study in patients with MND/ALS. PAA anticipates starting a Phase 2 study in H1 2024 that could lead to accelerated approval with the US Food and Drug Administration in 2026. PAA is preparing to start a pivotal field trial in dogs with B-Cell Lymphoma to enable product registration in the US in 2025. PAA has previously successfully completed a Phase 1 oncology clinical study of monepantel in humans and pilot studies in canine cancer.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
With four clinical trials kicking off, PharmAust is set for a busy 2022
Health & Biotech
ASX Health Stocks: After TGA approval in Australia, Telix now gets license to sell in Brazil
Health & Biotech
PharmAust’s upcoming Phase 1 clinical trials receive major boost with the production of smaller tablets
Health & Biotech
PharmAust marches ahead to Phase 1 trials on COVID-19 and motor neurone disease
News
Market Highlights and 5 ASX Small Caps to watch on Wednesday
Health & Biotech
ASX Health Stocks: Mesoblast jumps 10pc on Phase 3 trial results for chronic heart failure
Health & Biotech
PharmAust expands studies in NZ, one step closer towards a Phase 3 trial for canine cancer
News
10 at 10: These ASX stocks are worth their weight in gold this morning
Health & Biotech
PharmAust makes important progress during quarter ahead of multiple clinical trials of lead drug, monepantel
Health & Biotech
PharmAust’s lead drug MPL step closer to COVID-19 and MND human clinical trials
Health & Biotech
PharmAust doubles life expectancy of pet dogs with cancer, a major step towards commercialisation
Health & Biotech
ASX Health Stocks: Proteomics jumps 13pc on diabetes test
News
Market Highlights and 5 ASX Small Caps to watch on Monday
Health & Biotech
Merck’s COVID-19 breakthrough in the US gives boost to ASX- listed PharmAust
Health & Biotech
PharmAust reward loyal shareholders with attractively priced option offer
Health & Biotech
The ‘game changing’ waste-to-energy technology that could catapult PharmAust’s subsidiary Epichem into a $70b market
Health & Biotech